user
menu
letter
Sign InRegister
langEnglisharrow

Biotinylated Human HLA-A*24:02&B2M&WT-1 (CYTWNQMNL) Complex Protein (Monomer, MALS verified)

Cat. No. / Size
Price
Availability
Qty
HLW-H82E6-25ug
$125.00
In Stock - Delivery in 1-2 business days
HLW-H82E6-200ug
$700.00
In Stock - Delivery in 2-3 weeks
HLW-H82E6
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
Request Quote
Product Details
Performance Data
Reviews & Citations
Resources
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

HLA-A*2402 & B2M & WT-1 (CYTWNQMNL)

Source

Biotinylated Human HLA-A*24:02&B2M&WT-1 (CYTWNQMNL) Complex Protein (HLW-H82E6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Thr 305 (HLA-A*24:02) & Ile 21 - Met 119 (B2M) & CYTWNQMNL peptide (Accession # AAA59600.1 (HLA-A*24:02) & P61769 (B2M) & CYTWNQMNL).

Predicted N-terminus: Gly 25 & Ile 21

Molecular Characterization

Biotinylated Human HLA-A*24:02&B2M&WT-1 (CYTWNQMNL) Complex Protein is produced by co-expression of HLA and B2M loaded with WT-1 peptide.

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 35.8 kDa and 11.7 kDa. The protein migrates as 39-41 kDa and 10 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Labeling

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Purity

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 3 months under sterile conditions.
ACRO Quality Management System

Background

Wilms tumor gene 1 (WT1)，is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The human HLA-A*2402 WT-1 (CYTWNQMNL) complex protein is a complex of HLA-A*2402 of the MHC Class I, B2M and CYTWNQMNL peptide of the WT-1.